Biontech Cell & Gene Therapies Gmbh

Biontech Se

Tron—translationale Onkologie an Der Universitátsmedizin Der Johannes Gutenberg—universität Mainz Gemeinnützige Gmbh

Translationale Onkologie an Der Universitätsmedizin Der Johannes Gutenberg-Universität Mainz Gemeinnützige Gmbh

Ganymed Pharmaceuticals Ag

Biontech Ag

Tron-Translationale Onkologie an Der Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz

Tron Ggmbh

Biontech Diagnostics Gmbh

Translationale Onkologie an Der Universitätsmedizin Der Johannes Gutenbera-Universität Mainz Gemeinnützine Gmbh

Tron—translationale Onkologie an Der Universitätsmedizin Mainz Gemeinnützige Gmbh

Biotech Cell & Gene Thrapies Gmbh

Tron-Translationale Onkologie an Der Universitatsmedzin Der Johannes Gutenberg-Universitat Mainz

Tron—translationale Onkologie Ander Universitata Tsmedizin Der Johannes Gutenberg-Universitat Main

Ganymed Pharmaceuticals Gmbh

Petra Simon

Ugur Sahin

Tana Omokoko

Karolina Anna Mroz

Kathleen Hobohm

Ozlem Tureci

Christian Bender

Claudia Paret

Kirsten Vormbrock

Christoph Hartmann

Stefanie Hubich

Thomas Bukur

Thorsten Litzenberger

Özlem Türeci

Ralf-Holger Voss

Holger Hoff

Andrea Breitkreuz

Katharina Reinhard

Oezlem Tuereci

Lisa Hebich

Matthias Theobald

Özlem Öz

Matthias Birtel

Janina Caspar

Ralf Holger Voss

Michael Schäfer

Marta Magdalena Faryna

Annett Reichardt

ÖZlem Yildiz

The present invention relates to the treatment of cancer, in particular breast cancer, particularly triple-negative breast cancer. More particularly, the invention concerns methods for cancer treatment involving a specific set of tumor antigens.

Tumor antigens for determining cancer therapy

The present invention generally embraces the treatment of diseases by targeting cells expressing an antigen on the cell surface. In particular the invention relates to a method for stimulating, priming and/or expanding in vivo T cells genetically modified to express a chimeric antigen receptor (CAR) targeted to an antigen, comprising contacting the T cells with the antigen or a variant thereof in vivo. In one embodiment, the antigen or variant thereof is provided by administering a nucleic acid encoding the antigen or variant thereof.

Enhancing the effect of CAR-engineered T cells by means of nucleic acid vaccination

The present invention relates to the treatment of cancer, in particular breast cancer, particularly triple-negative breast cancer. More particularly, the invention concerns methods and means for cancer treatment involving a specific set of tumor antigens.

The present invention provides Claudin-6-specific immunoreceptors (T cell receptors and artificial T cell receptors (chimeric antigen receptors; CARs)) and T cell epitopes which are useful for immunotherapy.

Claudin-6-specific immunoreceptors and t cell epitopes

The present invention relates to efficient methods for providing antigen-specific lymphoid cells. These lymphoid cells may be used to provide antigen specific T cell receptors having a defined MHC restriction and to identify immunologically relevant T cell epitopes. Furthermore, the present invention relates to antigen-specific T cell receptors and T cell epitopes and their use in immunotherapy.

Antigen-specific T cell receptors and T cell epitopes

Enhancing the effect of car-engineered T cells by means of nucleic acid vaccination

The present invention relates to a kit and a method for determining whether a subject shows an immune response against an antigen.

Method and kit for determining whether a subject shows an immune response

Claudin-6-specific immunoreceptors and T cell epitopes

Growing community of inventors

Mainz, Germany

Petra Simon